Recombinant coagulation factor VIII

This page covers all Recombinant coagulation factor VIII drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Coagulation factor VIII, Coagulation factor VIII (intrinsic tenase complex).

Targets

Coagulation factor VIII · Coagulation factor VIII (intrinsic tenase complex)

Marketed (6)

• Kogenate (BAY14-2222) · Bayer · Hematology
  Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Kogenate (BAY 14-2222) · Bayer · Hematology
  Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Intravenous infusions of Xyntha · Pfizer · Hematology
  Xyntha is a recombinant coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.
• Efmoroctocog Alfa Injection [Eloctate] · The League of Clinical Research, Russia · Hematology
  Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients.
• OBIZUR · Baxalta now part of Shire · Hematology
  OBIZUR is a recombinant human Factor VIII that replaces deficient or dysfunctional Factor VIII to restore blood clotting ability in patients with hemophilia A.
• Moroctocog alfa (AF-CC) · Pfizer · Hematology
  Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.

Phase 3 pipeline (1)

• BAX 326 · Baxalta now part of Shire · Hematology
  BAX 326 is a recombinant human coagulation factor VIII designed to treat hemophilia A by replacing deficient or dysfunctional factor VIII.